JP2006176442A - Composition for sterilization containing glycoconjugate having peroxycarboxy group - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a new compound usable as an active ingredient of a composition capable of sterilizing equipment for medical care such as an endoscope, and having low smell; and to provide the composition containing the compound. <P>SOLUTION: The glycoconjugate (e.g. peroxy D-glucuronic acid) having a peroxycarboxy group, the aqueous composition containing the glycoconjugate, and the method for producing the glycoconjugate having the peroxycarboxy group, comprising a step for mixing the glycoconjugate having a carboxy group with an aqueous solution containing hydrogen peroxide are provided. <P>COPYRIGHT: (C)2006,JPO&NCIPI

Description

The present invention relates to a sterilizing composition. More specifically, the present invention relates to an aqueous composition for sterilization suitable for sterilization of medical equipment such as an endoscope.

A medical device such as an endoscope cannot be disposable and directly contacts a patient. Therefore, it is necessary to perform safer sterilization and use the next medical treatment. However, a small scale hospital often uses a single device in a short time. Therefore, as a composition used for sterilization of a medical device, a composition having an action of killing a wide range of microorganisms and capable of sterilizing a medical device in a short time is desired. In addition, from the viewpoint of health and safety for medical equipment cleaning workers, it is desirable that the compounds in the composition have as little odor as possible.

Conventionally, as a composition for cleaning and sterilizing medical equipment such as an endoscope, a composition containing an aldehyde such as glutaraldehyde as an active ingredient is known as a commercially available product. However, it has recently been pointed out that glutaraldehyde is a mutagenic substance, has a weak bactericidal action against spores, and causes allergies. In addition, due to the unique odor, it has been pointed out that there are obvious adverse effects on the health of medical equipment cleaning workers depending on the work environment. Recently, it has been known that a composition containing peracetic acid as an active ingredient (Patent Document 1) exhibits a bactericidal action against spores in a shorter time than a composition containing aldehyde as an active ingredient. This has an adverse effect on the working environment of medical equipment cleaning workers.

On the other hand, a sugar compound having a peroxycarboxyl group has not been known so far, and the bactericidal activity of a composition containing this is not known at all.
WO 2000/22931

The present invention provides a sterilizing composition that can be sterilized at a lower concentration and in a shorter time than peracetic acid that is currently in practical use, and that can improve the working environment of medical equipment cleaning workers by reducing odors. For the purpose. The composition of the present invention is preferably used for sterilization of medical equipment such as an endoscope.

The present inventors have intensively studied to solve the above problems, and found that an aqueous composition containing a sugar compound having a peroxycarboxyl group exhibits a bactericidal action in a short concentration and in a short time, and no odor is observed. It was. The present invention has been completed based on these findings.

That is, the present invention provides a sugar compound having a peroxycarboxyl group, particularly peroxy D-glucuronic acid.

According to another aspect of the present invention, there is provided a method for producing a sugar compound having a peroxycarboxyl group, the method comprising a step of mixing a sugar compound having a carboxyl group and an aqueous solution containing hydrogen peroxide; A method for producing a sugar compound having a peroxycarboxyl group, the method comprising: mixing a sugar compound having a lactone ring and an aqueous solution containing hydrogen peroxide; And the sugar compound having a lactone ring is D-glucurono-6,3-lactone.

According to yet another aspect of the present invention, an aqueous composition comprising a sugar compound having a peroxycarboxyl group; an aqueous composition comprising peroxy D-glucuronic acid; and any of the above aqueous compositions further comprising hydrogen peroxide; Aqueous composition comprising a sugar compound having a group, hydrogen peroxide, and a sugar compound in which one or more of the carboxyl groups of the sugar compound having a carboxyl group is substituted with a peroxycarboxyl group; a sugar compound having a carboxyl group is D-glucuron An aqueous composition comprising a sugar compound having a lactone ring, hydrogen peroxide, and a sugar compound having a peroxycarboxyl group obtained by opening one or more of the lactone rings; and a lactone ring. The aqueous composition in which the sugar compound having D-glucurono-6,3-lactone is provided.

According to a preferred embodiment of the present invention, one or more additives selected from the group consisting of a corrosion inhibitor, a pH adjuster, a metal sequestering agent, a stabilizer, and a surfactant are added to any of the above aqueous compositions. An aqueous composition is provided. Also, a dry form composition for preparing any of the above aqueous compositions; and a sugar compound having a carboxyl group or a lactone ring for preparing any of the above aqueous compositions A kit is provided by the present invention, comprising a composition comprising: an aqueous composition comprising hydrogen peroxide.

From another aspect of the present invention, there is provided a bactericidal agent containing any one of the above compositions, the bactericidal agent that is a bactericidal agent for medical equipment, and preferably a bactericidal agent in which the medical equipment is an endoscope. Also provided is the above kit provided as a disinfectant for a medical device, preferably the kit in which the medical device is an endoscope.

According to the present invention, a novel sugar compound having a peroxycarboxyl group is provided. In addition, a composition containing the novel compound, capable of sterilizing medical equipment such as an endoscope in a short time and having reduced odor is provided. The composition of the present invention can sterilize spores, for example, Bacillus subtilis, in a time shorter than that of peracetic acid, and can improve the working environment of cleaning workers by reducing odor. To do.

As used herein, the term `` sugar compound '' refers to the structural class generic names `` glycose '', `` aldose '', `` ketose '', `` glycitol '' or alditol. ), “Glyconic acid or aldonic acid”, “glycaric acid or aldaric acid”, “uronic acid” monosaccharide compounds and These mean polysaccharide compounds of two or more sugars optionally linked by glycosidic bonds. Further, functional groups such as hydroxyl groups and amino groups in these sugar compounds may be appropriately protected. The basic definition of “sugar compound” is described in detail in Chapter 2 of “MODERN CARBOHYDRATE CHEMISTRY” by Roger W. Binkley, for example.

Examples of the sugar compound having a carboxyl group used in the present invention include a group of compounds generally known as sugar acids, specifically glucuronic acid, gluconic acid, glucosamic acid, galacturonic acid, N-acetylneuraminic acid (sialic acid), Examples thereof include lactobionic acid and salts thereof. Glucuronic acid, galacturonic acid, lactobionic acid, and salts thereof are more preferable, and glucuronic acid and salts thereof are more preferable. But the sugar compound which has a carboxyl group used by this invention is not limited to these illustrations. As the sugar compound having a carboxyl group used in the present invention, one kind selected from the sugar acids exemplified above may be used, or two or more kinds may be used in combination. Moreover, the saccharide | sugar compound which has these carboxyl groups may be a polysaccharide of 2 or more sugars connected by the glycosidic bond, and functional groups such as hydroxyl groups in these saccharide compounds may be appropriately protected.

Specific examples of the sugar compound having a lactone used in the present invention include glucurono-6,3-lactone, araboascorbic acid, ascorbic acid, galactonolactone, glucono-1,5-lactone, and glonic acid γ-lactone. And mannono-1,4-lactone, glucurono-6,3-lactone, galactonolactone, and glucono-1,5-lactone are more preferable, and glucurono-6,3-lactone is more preferable. However, the sugar compound having a lactone used in the present invention is not limited to these examples. As the sugar compound having a lactone used in the present invention, one kind selected from those exemplified above may be used, or two or more kinds may be used in combination. Moreover, the saccharide | sugar compound which has these lactones may be a polysaccharide of 2 or more sugars connected by a glycosidic bond, and functional groups such as hydroxyl groups in these saccharide compounds may be appropriately protected.

For the physical properties and production methods of peroxycarboxyl groups, the methods described in pages 313 and 475 of D. Swern, “ORGANIC PEROXIDE” Wiley (1971) or “Industrial Organic Chemicals” Wiley-VCH, page 3641, etc. Can be used. The sugar compound having a peroxycarboxyl group provided in the present invention can also be obtained by reacting a sugar compound having a corresponding carboxyl group or a sugar compound having a lactone ring with an aqueous solution containing hydrogen peroxide.

As the sugar compound having a peroxycarboxyl group of the present invention, a peroxycarboxyl group obtained by a production method including a step of mixing a sugar compound having a carboxyl group or a sugar compound having a lactone and an aqueous solution containing hydrogen peroxide. Examples thereof include, but are preferably, peroxy D-glucuronic acid in which the carboxyl group of D-glucuronic acid is peroxidized. However, the sugar compound having a peroxycarboxyl group of the present invention used in the present invention is not limited to these examples. Peroxy D-glucuronic acid can be produced, for example, by a production method including a step of mixing D-glucuronic acid or D-glucurono-6,3-lactone and an aqueous solution containing hydrogen peroxide.

The aqueous composition of the present invention contains one or more sugar compounds having a peroxycarboxyl group. The concentration of the sugar compound having a peroxycarboxyl group in the aqueous composition of the present invention is from 0.1 mM to 2000 mM, preferably from 1 mM to 200 mM, and more preferably from 40 mM to 120 mM. In addition to the sugar compound having a peroxycarboxyl group, the aqueous composition of the present invention includes a sugar compound having a carboxyl group corresponding to the sugar compound having a peroxycarboxyl group or a sugar compound having a lactone and / or hydrogen peroxide. May be included.
Furthermore, the aqueous composition of the present invention may contain one or more additives in addition to the above components. Examples of additives include corrosion inhibitors, solubilizers, pH adjusters, anti-redeposition agents, stabilizers, metal sequestering agents, and cation, anion, or nonionic surfactants.

As the corrosion inhibitor, an agent suitable for the material of the medical device to be sterilized may be selected. For example, 1,2,3-benzotriazole, lower alkylbenzotriazole, hydroxybenzotriazole, lower alkylhydroxybenzotriazole, Carboxybenzotriazole, lower alkylcarboxybenzotriazole, benzimidazole, lower alkylbenzimidazole, hydroxybenzimidazole, lower alkylhydroxybenzimidazole, carboxybenzimidazole, lower alkylcarboxycarboxybenzimidazole, mercaptobenzothiazole, lower alkylmercaptobenzothiazole, hydroxymercapto Benzothiazole, lower alkylhydroxymercaptobenzothiazole, carboxymercaptobenzothiazo , Lower alkyl carboxymercaptobenzothiazole, sodium gluconate, sodium benzoate, butyl benzoate, monoethanolamine, triethanolamine, morpholine, sorbitol, erythritol, sodium phosphate, sodium tripolyphosphate, tetrasodium pyrophosphate, molybdate Examples include, but are not limited to, agents combining one or more compounds selected from sodium, sodium nitrite, sodium bisulfite, sodium metabisulfite, chromate, and borate. . As used herein, the term “lower alkyl” means a straight or branched, saturated or unsaturated hydrocarbon group having 1 to 6 carbon atoms.

When the composition of the present invention is used to treat equipment including copper, brass, bronze, or multimetallic systems, 1,2,3-benzotriazole and one or more lower alkyl benzoates. Corrosion inhibitors that are triazoles, hydroxybenzotriazoles, lower alkylhydroxybenzotriazoles, sodium molybdate, sodium nitrite, sodium bisulfite, sodium metabisulfite, chromates, borates, and mixtures thereof are preferably used. . A corrosion inhibitor containing 1,2,3-benzotriazole, sodium molybdate, and sodium nitrite is particularly preferably used. When the composition of the present invention is used for treating equipment containing carbon steel and stainless steel, for example, a corrosion inhibitor containing sodium benzoate, sodium nitrite, sodium molybdate and the like is preferably used. It is done. When the composition of the present invention is used for treating equipment containing carbon steel and / or stainless steel, for example, a corrosion inhibitor containing sodium nitrate and / or sodium molybdate is preferably used. The total amount of corrosion inhibitor present in the aqueous composition of the present invention is typically 0.1% to about 30% by weight, based on the total weight of the composition. The amount of 1,2,3-benzotriazole is preferably 0.1% to about 3.0% by weight, more preferably 0.5% to about 2.0% by weight.

Where the corrosion inhibitor is sparingly soluble in the aqueous composition of the present invention containing a peracid, the composition of the present invention may further comprise a solubilizing agent such as an alkylene glycol. As used herein, the term “alkylene glycol” refers to, for example, ethylene glycol, propylene glycol, dialkylene glycol (eg, diethylene glycol), trialkylene glycol (eg, triethylene glycol), and the corresponding mono- and dialkyl thereof. Glycol such as ether. Here, the alkyl ether is a lower alkyl ether having 1 to 6 carbon atoms (for example, methyl, ethyl, or propyl ether). Particularly preferably, the composition of the present invention contains propylene glycol as a solubilizer, and the propylene glycol is preferably contained in the composition of the present invention at a concentration of about 3 to 10 times that of the corrosion inhibitor. For example, propylene glycol is contained in the aqueous composition of the present invention at about 3.5% to 6.5% by weight relative to 1,2,3-benzotriazole contained at about 1% by weight of the aqueous composition of the present invention. It is preferable.

pH adjusters include acids that are compatible with the composition of the present invention and compatible with the environment, such as citric acid, acetic acid, tartaric acid, malic acid, lactic acid, glycolic acid, succinic acid, glutaric acid, or adipic acid. Organic acids and salts thereof, inorganic acids such as phosphoric acid and sulfuric acid and salts thereof, and bases such as ammonium hydroxide and alkali metal hydroxide can be used. However, the pH adjuster that can be used in the present invention is not limited thereto. The concentration of the pH adjusting agent in the composition of the present invention is preferably 20% by mass or less, particularly preferably 0.1% by mass to 10% by mass, based on the total mass of the composition.

The composition of the present invention preferably contains a heavy metal sequestering agent as an optional component. In the present specification, the heavy metal ion sequestering agent means a component that acts to sequester (metal chelate) heavy metal ions, and even when these components have the ability to chelate calcium and magnesium, iron, manganese, and copper It means a component that binds more selectively to such heavy metal ions. The heavy metal ion sequestering agent is usually 0.005% to 20% by weight, preferably 0.1% to 10% by weight, more preferably 0.25% by weight based on the total weight of the composition in the composition of the present invention. % To 7.5% by weight, most preferably at a level of 0.5% to 5% by weight. Heavy sequestering agents suitable for addition to the compositions of the present invention include organic phosphonates such as aminoalkylene poly (alkylene phosphonates), alkali metal ethane 1-hydroxydiphosphonates, and nitrilo trimethylene. Examples include phosphonates. Of these, diethylenetriaminepenta (methylenephosphonic acid), ethylenediaminetri (methylenephosphonate) hexamethylenediaminetetra (methylenephosphonic acid), and hydroxy-ethylene 1,1 diphosphonate are preferred.

Other sequestering agents preferred for addition to the compositions of the present invention include nitrilotriacetic acid and polyaminocarboxylic acids such as ethylenediaminotetraacetic acid, ethylenetriaminepentaacetic acid, ethylenediamine disuccinic acid, ethylenediamine diglutaric acid, 2 -Hydroxypropylenediamine disuccinic acid or any salt thereof. Particularly preferred are ethylenediamine-N, N′-disuccinic acid (EDDS) or alkali metals, alkaline earth metals, ammonium or substituted ammonium salts thereof, or mixtures thereof.

Other preferable heavy metal ion sequestering agents to be added to the composition of the present invention are described in, for example, European Patent Publication No. 317,542 and European Patent Publication No. 399,133. Iminodiacetic acid derivatives such as 2-hydroxyethyldiacetic acid or glyceryliminodiacetic acid, iminodiacetic acid-N-2-hydroxypropylsulfonic acid and aspartic acid N- described in EP 516,102 Carboxymethyl N-2-hydroxypropyl-3-sulfonic acid sequestering agent, and β-alanine-N, N′-diacetic acid, aspartic acid-N, N ′ described in European Patent Publication No. 509,382 -Diacetic acid, aspartic acid-N-monoacetic acid and iminodisuccinic acid sequestering agent. EP-A 476,257 describes suitable amino-based blocking agents. EP-A 510,331 describes suitable blocking agents derived from collagen, keratin or casein. EP 528,859 describes suitable alkyliminodiacetic acid sequestering agents. Also suitable are dipicolinic acid and 2-phosphonobutane-1,2,4-tricarboxylic acid. Also suitable are glycinamide-N, N′-disuccinic acid (GADS), ethylenediamine-N, N′-diglutaric acid (EDDG), and 2-hydroxypropylenediamine-N, N′-disuccinic acid (HPDDS). It is.
However, the heavy metal ion sequestering agent suitable for addition to the composition of the present invention is not limited to the above examples.

A known stabilizer may be used as the stabilizer, and examples thereof include phosphate, 8-hydroxyquinoline, stannic acid, sulfolene, sulfolane, sulfoxide, sulfone, and sulfonic acid. In the composition of the present invention, phosphate is a preferred stabilizer. Preferably, the composition of the present invention comprises from about 0.001% to about 0.5% by weight phosphate, based on the total weight of the composition. The phosphate is selected from the group consisting of sodium orthophosphate, potassium orthophosphate, sodium pyrophosphate, potassium pyrophosphate, sodium polyphosphate, potassium polyphosphate, and combinations thereof.

Also, the composition of the present invention may optionally contain up to about 30% by weight surfactant based on the total weight of the composition. As the surfactant, a surfactant that is stable against oxidation and decomposition in the presence of peroxycarboxylic acid and hydrogen peroxide in an acidic aqueous medium can be used. Preferably, a surfactant that is easily oxidized is used. avoid. Suitable surfactants can be selected from nonionic, anionic, amphoteric or cationic surfactants.
Preferred surfactants to be added to the composition of the present invention include nonionic surfactants, specifically, polyethylene / polypropylene block polymer type surfactants, polyoxyethylene alkylphenyl ether type interfaces. Activators, polyoxyethylene ether surfactants, polyoxyethylene sorbitan surfactants, and the like. The surfactant added to the composition of the present invention is not limited to these.

As the anti-redeposition agent, those having a function of keeping dirt or the like detached from the medical device suspended in the liquid can be used. For example, organic water-soluble colloids (eg starch, gelatin, starch ether carboxylic acid or ether sulfonic acid salt, cellulose, cellulose ether, cellulose ether carboxylic acid or ether sulfonic acid salt, or cellulose or starch acidity Sulfate salts). A water-soluble polyamide containing an acidic group can also be preferably used. Furthermore, starch derivatives other than those described above, such as aldehyde starch, can also be used. But the anti-redeposition agent added to the composition of this invention is not limited to these illustrations.
As the anti-redeposition agent, one or more selected from the group consisting of the above compounds exemplified as the anti-redeposition agent can be used. The concentration of the anti-redeposition agent in the aqueous composition of the present invention is preferably 5% by mass or less, particularly preferably 2% by mass or less, based on the total mass of the composition.

As used herein, the term “sterilization” includes meanings such as “cleaning”, “disinfecting”, and “antibacterial”. By examining conditions such as the concentration of the sugar compound having a peroxycarboxylic acid and the contact time with the medical device, it is possible to “sterilize” the medical device using the aqueous composition of the present invention. With the aqueous composition of the present invention, a spore that is a particularly highly resistant bacterium, such as Bacillus subtilis, can be killed in a time as short as that of peracetic acid. In addition, the aqueous composition of the present invention does not cause deterioration of the medical device cleaning work environment such as acetic acid odor. The use of the bactericidal agent containing the aqueous composition of the present invention is not particularly limited, but is suitable for sterilization of medical equipment on the premise of repeated use, and particularly dental equipment and medical surgery that require sterilization in a short time. Suitable for sterilization of medical devices, particularly preferably endoscopes.

Although the sterilization method using the aqueous composition for sterilization of the present invention is not particularly limited, a method of sterilizing a medical device by immersing the medical device in the aqueous composition of the present invention and bringing them into contact with each other is preferable. In the immersion, the aqueous composition may be stirred, a medical device may be shaken, or an automatic washing machine may be used. In addition, a step of washing the medical device before or after the immersion may be included, and a step of wiping the medical device with sterilized gauze or the like after the immersion or drying with a dryer or the like may be included. . The immersion time is not particularly limited as long as it is about 15 seconds or longer, but sufficient sterilization is possible in 5 minutes or less. Therefore, the sterilization operation should be completed within the time when the medical device is used in a normal medical diagnosis. Can do.

The aqueous composition for sterilization of the present invention can be provided as it is as a sterilizing agent. However, a saccharide compound having a carboxyl group or a saccharide compound having a lactone or an aqueous composition containing these and an aqueous composition containing hydrogen peroxide are provided. It is provided as a kit and can be mixed and used for use. If necessary, the mixture can be used after diluting with water. In addition, a sugar compound having a carboxyl group or a sugar compound having a lactone and a mixture of the above additives can be provided in a dry form and dissolved in an aqueous solvent containing hydrogen peroxide when used.

EXAMPLES Hereinafter, the present invention will be described more specifically with reference to examples. However, the scope of the present invention is not limited to these examples.
(1) Method for measuring the concentration of a sugar compound having a peroxycarboxyl group The concentration of a sugar compound having a peroxycarboxyl group in a test solution is determined according to the following peracetic acid described in Analyst, 87 , 653-657 (1962). It measured according to the titration method.
Titration method of peracetic acid 200 μl of test solution is precisely weighed and added to 100 ml of 0.1 mol / l acetic acid solution. To the obtained sample solution, 10 ml of a 15 w / v% potassium iodide aqueous solution is added, and simultaneously time measurement is started. After 1 minute, the released iodine is titrated with a 0.1N sodium thiosulfate solution until the blue color disappears using a starch indicator. Record the titration value (X ₁ ml) and time (t ₁ sec) when the blue color returns after a while. This is repeated several times within 10 minutes from the start of the reaction. (Subsequently, X ₁ , X ₂ , t ₁ , t ₂ , etc.) Then add several drops of 0.1 mol / l ammonium molybdate solution to the reaction mixture, let stand for 5 minutes, perform titration, and add 0.1N total thiol Obtain the amount of sodium sulfate solution Xt. Plotting the logarithm [log (Xt-Xi)] of the color time ti and sodium thiosulfate solution of 0.1N, obtaining the sodium thiosulfate solution amount X ₀ of 0.1N when the t = 0 from the intercept.
The content of the sugar compound from X ₀ have the peroxy carboxylic group, to calculate the hydrogen peroxide content from (Xt-X _0).

Example 1.
2.00 g of D-glucuronic acid was added to 6.0 ml of 30% hydrogen peroxide solution while stirring at room temperature. When the concentration was measured by the measurement method 60 hours after the start of the reaction, it was confirmed that 314 mM of a sugar compound having a peroxycarboxyl group and 7403 mM of hydrogen peroxide were contained.
Example 2.
2.00 g of D-galacturonic acid was added to 6.0 ml of 30% hydrogen peroxide water while stirring at room temperature. When the concentration was measured by the above measuring method 42 hours after the start of the reaction, it was confirmed that 449 mM of a sugar compound having a peroxycarboxyl group was contained.
Example 3.
3.69 g of lactobionic acid was added to 4.0 ml of 30% aqueous hydrogen peroxide with stirring at room temperature. When the concentration was measured by the measurement method 42 hours after the start of the reaction, it was confirmed that 49 mM of a sugar compound having a peroxycarboxyl group was contained.
Example 4.
2.00 g of glucurono-6,3-lactone was added to 6.0 ml of 30% aqueous hydrogen peroxide while stirring at room temperature. When the concentration was measured by the above measuring method 15 hours after the start of the reaction, it was confirmed that the sugar compound having a peroxycarboxyl group contained 722 mM and hydrogen peroxide was 7731 mM.

Example 5: Method for evaluating antimicrobial activity The antimicrobial activity of the composition of the present invention against spores was evaluated.
A spore of Bacillus subtilis IFO3134 was prepared with reference to the method for preparing the spore stock solution of Eisei No. 10 (January 29, 1996). Specifically, Bacillus subtilis IFO3134 was cultured on Nutrient Agar (Difco) for 1 week at 37 ° C., and a spore formation rate of about 90% was confirmed. The bacterium was suspended in 3 mL of sterilized water, and heat-treated at 65 ° C. for 30 minutes with shaking (160 rpm) to kill the vegetative form. After centrifugation (3000 rpm), the supernatant was discarded and 3 mL of sterilized water was added to obtain a spore stock solution. This spore stock solution was adjusted to 1.1 × 10 ⁹ cfu / mL and subjected to the following antimicrobial activity evaluation.

Antimicrobial activity evaluation was performed according to the method of Sakagami et al. (J. Antibact. Antifung. Agents., 26, 605-601, 1998). Specifically, 25 μL of the spore suspension prepared by the above-described method was added to 225 μL of each sample aqueous solution subjected to 0.2 μm filter filtration, and reacted at 25 ° C. for a certain time (bacterial concentration after mixing: 1.1 × 10 ⁸ cfu / mL). 2 μL was sampled from this aqueous solution, added to 2 mL of SCDLP medium (Nissui Pharmaceutical), and cultured at 160 rpm and 37 ° C. for 48 hours to examine the presence or absence of bacterial growth. In addition, 25 μL of the same reaction solution was added to 225 μL of a mixed aqueous solution of 0.1N sodium thiosulfate and 1% catalase to inactivate peracid and hydrogen peroxide, and then diluted as appropriate to obtain a SCDLP agar medium (Nissui Pharmaceutical, 25 mL / Petri dishes were seeded with 100 μL, and the number of remaining bacteria was counted after culturing at 37 ° C. for 48 hours.

The aqueous solution prepared in Example 1 was diluted with distilled water for injection (Photopharmaceutical) so that the peracid concentration was 40 mM and 80 mM, and antibacterial activity was evaluated according to the method described above. The results of plotting the contact time and the number of remaining bacteria are shown in FIG. In addition, the dotted line in the figure is an approximate straight line for predicting the contact time when the number of bacteria having a logarithmic value of 12 that can guarantee sterility is reduced from measured data.
In addition, when the antibacterial activity of hydrogen peroxide water having the same concentration (900 mM and 1800 mM) as that of hydrogen peroxide contained in these diluted solutions was separately evaluated, no decrease in the number of remaining bacteria was observed. It was.

Comparative Example 1.
In the same manner as in Example 1, the antibacterial activity was evaluated for peracetic acid (concentration 40 mM, 80 mM). The results are shown in FIG.
From the results of FIGS. 1 and 2, it was found that the aqueous composition of the present invention exhibits a strong antibacterial activity equivalent to or better than that of peracetic acid. Peracetic acid has a strong acetic acid odor in addition to a peroxy acid-derived irritating odor, so when actually handling it as a disinfectant, the load on workers was great, and measures such as ventilation were essential. Since the aqueous composition has almost no odor, the operator can disinfect the medical device without any load.

It is the figure which plotted the contact time and the number of residual bacteria of the aqueous composition of this invention, and a microbe. It is the figure which plotted the contact time and the number of residual bacteria of peracetic acid and a microbe.

Claims (25)

A sugar compound having a peroxycarboxyl group. Peroxy D-glucuronic acid. A method for producing a sugar compound having a peroxycarboxyl group, the method comprising mixing a sugar compound having a carboxyl group and an aqueous solution containing hydrogen peroxide. The production method according to claim 3, wherein the sugar compound having a carboxyl group is D-glucuronic acid. A method for producing a sugar compound having a peroxycarboxyl group, the method comprising mixing a sugar compound having a lactone ring and an aqueous solution containing hydrogen peroxide. 6. The production method according to claim 5, wherein the sugar compound having a lactone ring is D-glucurono-6,3-lactone. An aqueous composition comprising a sugar compound having a peroxycarboxyl group. An aqueous composition comprising peroxy D-glucuronic acid. The aqueous composition according to claim 7 or 8, further comprising hydrogen peroxide. An aqueous composition comprising a sugar compound having a carboxyl group, hydrogen peroxide, and a sugar compound in which one or more of the carboxyl groups of the sugar compound having a carboxyl group are substituted with a peroxycarboxyl group. The aqueous composition according to claim 10, wherein the sugar compound having a carboxyl group is D-glucuronic acid. An aqueous composition comprising a sugar compound having a lactone ring, hydrogen peroxide, and a sugar compound having a peroxycarboxyl group obtained by opening one or more of the lactone rings. The aqueous composition according to claim 12, wherein the sugar compound having a lactone ring is D-glucurono-6,3-lactone. The aqueous composition according to any one of claims 7 to 13, comprising a corrosion inhibitor. The aqueous composition according to any one of claims 7 to 14, comprising a pH adjuster. The aqueous composition according to any one of claims 7 to 15, comprising a sequestering agent. The aqueous composition according to any one of claims 7 to 16, comprising a stabilizer. The aqueous composition according to any one of claims 7 to 17, comprising a surfactant. A composition in dry form for preparing the aqueous composition according to any one of claims 7-18. A composition containing a sugar compound having a carboxyl group or a sugar compound having a lactone ring for preparing the aqueous composition according to any one of claims 7 to 18, and an aqueous composition containing hydrogen peroxide, Including kit. A bactericide containing the composition according to any one of claims 7 to 19. The disinfectant according to claim 21, which is a disinfectant for medical equipment. The disinfectant according to claim 22, wherein the medical device is an endoscope. 21. The kit according to claim 20, which is provided as a disinfectant for medical equipment. The kit according to claim 24, wherein the medical device is an endoscope.

Images